<DOC>
	<DOCNO>NCT00225849</DOCNO>
	<brief_summary>The purpose study investigate balance risk benefit primary prevention Aspirin elderly Japanese patient one cerebro/cardiovascular risk factor</brief_summary>
	<brief_title>Japanese Primary Prevention Project With Aspirin</brief_title>
	<detailed_description>Cerebro/cardiovascular ( CV ) death account approximately 30 % total death Japan therefore important establish preventive treatment CV event point public health . The guideline propose joint study group center Japanese Circulation Society , recommend administration aspirin patient multiple risk factor primary prevention arteriosclerotic disease . In addition , 2002 AHA guideline recommend use aspirin patient 10 % high 10-year risk CV event . However , description found randomize , comparative study result epidemiological data obtain outside Japan , epidemiological data available Japan would allow prediction selection patient could benefit primary prevention aspirin . Although benefit aspirin secondary prevention proven Japanese patient , benefit primary prevention still controversial . JPPP multicenter , open-label , centrally randomize , control trial . In total , 10,000 elderly patient one CV risk factor ( age 60–85 year combine hypertension , hyperlipidemia , and/or diabetes ) assign enteric-coated aspirin ( 100mg/day ) control . The primary endpoint composite event CV death , nonfatal stroke ( cause ) nonfatal myocardial infarction .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Elderly patient previously diagnose arteriosclerotic disease , include coronary artery disease cerebrovascular disease , meet one follow criterion ( medication one follow condition ) . Hypertension : SBP ≥ 140 mmHg DBP ≥ 90 mmHg Hyperlipidemia : Hypercholesterolemia ( total cholesterol ≥ 220 mg/dL LDL cholesterol ≥ 140 mg/dL ) Hypertriglyceridemia ( Triglycerides ≥ 150 mg/dL ) LowHDL cholesterolemia ( HDL cholesterol &lt; 40 mg/dL ) Diabetes : Fasting morning blood glucose ≥ 126 mg/dL casual blood glucose ≥ 200 mg/dL blood glucose 2 hr 75g glucose tolerance test ≥ 200 mg/dL , HbA1c ≥ 6.5 % Age : 60 85 year Patients give write consent participation study Patients history coronary artery disease cerebrovascular disease ( include transient ischemic attack ) Patients arteriosclerotic disease require surgery intervention Patients may atrial fibrillation Patients treat aspirin , antiplatelet agent anticoagulants Patients use NSAIDs chronically Patients history hypersensitivity aspirin salicylic acid Patients peptic ulcer Patients bleed tendency Patients serious blood abnormality Patients aspirinsensitive asthma history Patients otherwise judge investigator unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Aspirin</keyword>
	<keyword>Primary prevention</keyword>
</DOC>